PTJ
ADMA icon

Paul Tudor Jones’s ADMA Biologics ADMA Stock Holding History

Paul Tudor Jones’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-708,089
Closed -$6.38M – 3469
2026
Q1 		$6.38M Buy
708,089
+628,583
+791% +$9.92M 0.01% 1024
2025
Q4 		$1.45M Buy
79,506
+13,755
+21% +$232K ﹤0.01% 2038
2025
Q3 		$964K Buy
+65,751
New +$1.13M ﹤0.01% 2293
2025
Q1 		– Sell
-22,614
Closed -$391K – 2983
2024
Q4 		$388K Buy
22,614
+11,869
+110% +$223K ﹤0.01% 2412
2024
Q3 		$215K Sell
10,745
-1,377
-11% -$21.4K ﹤0.01% 2504
2024
Q2 		$136K Buy
+12,122
New +$102K ﹤0.01% 2190
2023
Q4 		– Sell
-173,818
Closed -$622K – 2307
2023
Q3 		$622K Buy
173,818
+146,866
+545% +$565K 0.01% 1567
2023
Q2 		$99.5K Buy
+26,952
New +$99.9K ﹤0.01% 2295
2020
Q3 		– Sell
-20,042
Closed -$59K – 1243
2020
Q2 		$59K Sell
20,042
-74,503
-79% -$214K ﹤0.01% 1104
2020
Q1 		$272K Buy
+94,545
New +$327K 0.02% 712

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Paul Tudor Jones's ADMA Position: Q2 2026 in Review

Paul Tudor Jones sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 708,089 shares — an estimated $6.38M sold.

Paul Tudor Jones first reported a position in ADMA in Q1 2020 and held it in 10 quarters. The position peaked at $6.38M in Q1 2026. 321 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Paul Tudor Jones reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 708,089 ADMA Biologics shares in Q2 2026, an estimated $6.38M.
  • Paul Tudor Jones first reported a position in ADMA Biologics in Q1 2020 and held it in 10 quarters.
  • Paul Tudor Jones's ADMA Biologics position peaked at $6.38M in Q1 2026.
  • 321 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.